Citeline Podcasts

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 5, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time – Revolution’s daraxonrasib makes splash at ASCO; Merck

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-UH6HET2LLNGUJBCSJ3UA2KLGCQ/

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs, as well as Generics Bulletin Executive Editor David Wallace, consider the implications of the US Supreme Court decision upholding the skinny labeling system (:37), including how the generic industry will adapt going forward (9:02). They also discuss the stakeholder comments the US Food and Drug Administration received during a public hearing on the National Priority Voucher and their potential impact on the program’s future (10:50).

More On These Topics From The Pink Sheet

US Supreme Court Retains Skinny Labeling System, Backs Hikma

Stakeholders Want Clearer Eligibility Criteria For US FDA’s

NPV Program Facing Legal Durability Questions As Public

Grading US FDA’s National Priority Voucher Program After One

CNPV Public Meeting Questions: US FDA Seeks Talking Points

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年5月29日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: GLP-1受体激动剂能否辅助抗癌；诺华公司的心血管战略；礼来公司的雷塔鲁肽在肥胖症治疗方面前景可期；礼来公司加大对细胞与基因疗法的投入；以及中国新数据保护法规对商业领域的影响。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-QIUHRJ2UTNCIXB4T2CVZPNXG24/

Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine.

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential impact a mandated nondisclosure agreement could have on US Food and Drug Administration activities and its employees (:34), as well as the changes the agency’s hiring push caused to user fee reauthorization efforts (13:50).

More On These Topics From The Pink Sheet

Proposed Government Nondisclosure Agreement Could Include US

Audio roundup of selected biopharma industry content from Scrip over the business week ended May 22, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time – industry grapples with MFN fallout; rapid early trials

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-I3FWWY2VRBAJND24H372L2CGIY/

"Biotechs are running increasingly complex clinical trials with lean teams, tight budgets, and growing pressure to deliver faster results. In this episode, Claire Riches, VP, Clinical Solutions, Citeline is joined by Carrie Melvin, Head of Clinical Operations and Data Management, Lantheus to explore how smarter outsourcing, stronger CRO partnerships, and patient‑focused trial design can improve execution, control costs, and reduce operational risk, while avoiding unnecessary burden on sites and participants.

View the video series and find out more information here: https://www.citeline.com/biotech"

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年5月22日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 行业正努力应对最惠国待遇政策带来的影响；早期临床试验进展迅速推动中国市场合作；艾伯维（AbbVie）寻求在神经科学领域扩张；环状DNA会是下一个重大突破吗？；以及Regeneron公司的fianlimab遭遇挫折。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-I3FWWY2VRBAJND24H372L2CGIY/

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the impact of the US Food and Drug Administration’s purge of multiple center directors and other senior executives in the wake of Commissioner Martin Makary’s resignation (:34). They also discuss the agency’s potential new direction and the initial comments of some of its new leaders (15:12).

More On These Topics From The Pink Sheet

US FDA’s Real-Time Clinical Trial Pilot Seeks Expansion As

Acting CDER Director Warns AI Over-Reliance Will Trigger GMP

US FDA Chief AI Officer Departs, But Ousted Chief Of Staff,

13 Center Directors Across CDER, CBER In 17 Months … And

Diamantas Extends Olive Branch To US FDA Staff Amid Senior